AstraZeneca announced that its breast cancer pill did not meet efficacy endpoints in a pivotal trial evaluating it as a first-line treatment for advanced tumors. The failure represents a setback for the company's oncology pipeline.
Clinical trial failures directly impact a company's drug development prospects and can affect investor confidence in its pipeline.
No published comments yet.
The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.
Recent SEC-reported share and derivative transactions in ASTRAZENECA PLC.
1 discretionary purchases · 0 discretionary sales
Confidence: Low
| Insiders | Activity | Description | Shares | Avg. price / share | Est. value | Trade date |
|---|---|---|---|---|---|---|
| See RemarksSharma Mani | Non-informative buy | Ordinary SharesCompany grant or award (A) | 1 | — | — | Sep 8, 2026 |
| See RemarksSharma Mani | Informative buy | Ordinary SharesOpen-market or private transaction |
| Insiders | Activity | Description | Shares | Avg. price / share | Est. value | Trade date |
|---|---|---|---|---|---|---|
| See RemarksSharma Mani | Informative sell | Ordinary SharesOpen-market or private transaction (S) | 11,893 | $185.78 | $2,209,482 | May 20, 2026 |
| See RemarksSharma Mani | Non-informative buy |
As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.
Quarterly reported positions. These filings can arrive up to 45 days after quarter-end and are not real-time trades.
Institutional ownership: 53.29%
Open short positions reported twice monthly; this is not daily short-sale volume.
Recent reported earnings per share compared with the analyst consensus available from Nasdaq.
| 20.23 |
| $160.57 |
| $3,249 |
| Aug 8, 2026 |
| SVP, Group ControllerSharma Mani | Non-informative buy | Ordinary SharesCompany grant or award (A) | 2 | — | — | Aug 6, 2026 |
| See RemarksSharma Mani | Non-informative buy | Ordinary SharesCompany grant or award (A) | 2 | — | — | Jul 6, 2026 |
| See RemarksSharma Mani | Non-informative buy | Ordinary SharesCompany grant or award (A) | 1 | — | — | Jun 8, 2026 |
| Ordinary SharesCompany grant or award (A) |
| 1 |
| — |
| — |
| May 6, 2026 |
| See RemarksSharma Mani | Non-informative buy | Ordinary SharesCompany grant or award (A) | 1 | — | — | Apr 7, 2026 |
| Owner | Activity | Change | Shares held | Value (thousands) | Reported |
|---|---|---|---|---|---|
| Investor Ab | Unchanged | 0 (0%) | 51,587,810 | $8,262,820 | 6/30/2026 |
| Vanguard Capital Management Llc | Buy | 346,048 (0.768%) | 45,386,190 | $7,269,506 | 6/30/2026 |
| Capital International Investors | Buy | 183,057 (0.532%) | 34,576,070 | $5,538,049 | 6/30/2026 |
| Norges Bank | Buy | 33,226,081 (5207.107%) | 33,864,172 | $5,424,024 | 6/30/2026 |
| Capital World Investors | Buy | 1,810,554 (6.406%) | 30,075,134 | $4,817,134 | 6/30/2026 |
| Fmr Llc | Sell | -706,460 (-2.387%) | 28,895,264 | $4,628,154 | 6/30/2026 |
| Wellington Management Group Llp | Buy | 4,786,158 (20.151%) | 28,537,243 | $4,570,810 | 6/30/2026 |
| Legal & General Group Plc | Sell | -99,733 (-0.386%) | 25,750,245 | $4,124,417 | 6/30/2026 |
| Jpmorgan Chase & Co | Buy | 613,901 (3.302%) | 19,204,823 | $3,076,037 | 6/30/2026 |
| Vanguard Asset Management, Ltd | Buy | 177,605 (0.958%) | 18,712,920 | $2,997,248 | 6/30/2026 |
| Primecap Management Co/Ca/ | Sell | -118,530 (-0.651%) | 18,095,178 | $2,898,305 | 6/30/2026 |
| Bank Of America Corp /De/ | Sell | -1,367,865 (-7.177%) | 17,690,462 | $2,833,481 | 6/30/2026 |
Source: Nasdaq
| Settlement date | Short interest | Avg. daily volume | Change vs. previous report | Days to cover |
|---|---|---|---|---|
| Aug 31, 2026 | 2,895,178 | 3,255,831 | +52.97% | 1.00 |
| Aug 14, 2026 | 1,892,646 | 5,542,310 | +2.95% | 1.00 |
| Jul 31, 2026 | 1,838,477 | 2,534,340 | -27.44% | 1.00 |
| Jul 15, 2026 | 2,533,640 | 3,192,074 | +65.59% | 1.00 |
| Jun 30, 2026 | 1,530,055 | 2,010,756 | +15.34% | 1.00 |
| Jun 15, 2026 | 1,326,546 | 2,118,908 | -22.84% | 1.00 |
| May 29, 2026 | 1,719,165 | 1,783,538 | -20.50% | 1.00 |
| May 15, 2026 | 2,162,492 | 1,807,324 | +18.11% | 1.20 |
Source: FINRA Consolidated Short Interest
| Fiscal quarter | Reported | EPS | Consensus | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 27, 2026 | 2.63 | 2.5 | +5.2% |
| Mar 2026 | Apr 29, 2026 | 2.58 | 2.57 | +0.39% |
| Dec 2025 | Feb 10, 2026 | 1.06 | 2.18 | -51.38% |
| Sep 2025 | Nov 6, 2025 | 2.38 | 2.28 | +4.39% |
Source: Nasdaq
